Five sessions of hyperbaric oxygen for critically ill patients with COVID-19-induced ARDS: A randomised, open label, phase II trial
Open Access
- 24 July 2024
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 232, 107744
Abstract
No abstract availableKeywords
Funding Information
- Swedish Research Council
This publication has 22 references indexed in Scilit:
- Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trialHeliyon, 2023
- Clinical and biochemical short-term effects of hyperbaric oxygen therapy on SARS-Cov-2+ hospitalized patients with hypoxemic respiratory failureRespiratory Medicine, 2023
- Innate immunity: the first line of defense against SARS-CoV-2Nature Immunology, 2022
- Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19BMJ Open, 2021
- Immune dysregulation and system pathology in COVID-19Virulence, 2021
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19?Medical Hypotheses, 2020
- Why COVID-19 Silent Hypoxemia Is Baffling to PhysiciansAmerican Journal of Respiratory and Critical Care Medicine, 2020
- The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review2020
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsBMJ, 2013